Clinical Trial Update: A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 [Phase 2]

View source ↗

Summary

A Phase 2 randomized study evaluated the safety, tolerability, and antiviral activity of ABT-450, ABT-333, and ABT-072 in Hepatitis C; the trial is completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-072
• ABT-333 (ABT-333)
• ABT-450 (atazanavir)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Hepatitis C, HCV | Phase 2 | Status: COMPLETED | Results posted: 2015-01-08